Oceansbio improves people's health and well-being powered by pioneering medical devices and a breakthrough in neuropsychology.



Oceansbio CEO

Hyunwoong Lee

Oceansbio is a company dedicated to developing treatments for neurological disorders such as depression and epilepsy, utilizing its expertise in biomedical engineering and neurosciences. With our advanced technology, we aim to create a future where every patient with neurological disorders can access hyper-personalized treatments. 

The non-invasive TaVNS device for depression treatment has completed the development of its commercial model and is on the verge of clinical trials. Additionally, we plan to complete the development of implantable VNS (iVNS) this year and unveil it at major university hospitals.

We will quickly establish ourselves as the one and only electroceuticals company in Korea specializing in TaVNS and iVNS for the treatment of depression and epilepsy. Moreover, by collecting and interpreting the biological data, we aspire to open new possibilities in providing personalized solutions for neurological disorders. Through this initiative, we will devote ourselves to relieving the pain of drug-resistant patients and sharing the burden of their families, eventually gaining international recognition and contributing to addressing societal issues. 

We are poised to take a new leap with our outstanding K-electroceuticals. Your support always keeps us moving forward. 

Sincerely,

Hyun-Woong Lee, CEO

OceansBio Inc




Oceansbio improves people's health and well-being 
powered by pioneering medical devices and a breakthrough in neuropsychology.




Oceansbio CEO

Hyunwoong

Lee

Oceansbio is a company dedicated to developing treatments for neurological disorders such as depression and epilepsy, utilizing its expertise in biomedical engineering and neurosciences. With our advanced technology, we aim to create a future where every patient with neurological disorders can access hyper-personalized treatments.

The non-invasive TaVNS device for depression treatment has completed the development of its commercial model and is on the verge of clinical trials. Additionally, we plan to complete the development of implantable VNS (iVNS) this year and unveil it at major university hospitals.

We will quickly establish ourselves as the one and only electroceuticals company in Korea specializing in TaVNS and iVNS for the treatment of depression and epilepsy. Moreover, by collecting and interpreting the biological data, we aspire to open new possibilities in providing personalized solutions for neurological disorders. Through this initiative, we will devote ourselves to relieving the pain of drug-resistant patients and sharing the burden of their families, eventually gaining international recognition and contributing to addressing societal issues. 

We are poised to take a new leap with our outstanding K-electroceuticals. Your support always keeps us moving forward. 

Sincerely,

Hyun-Woong Lee, CEO

OceansBio Inc